KR100505772B1 - 개선된정맥투여용농축주사액및주입액 - Google Patents

개선된정맥투여용농축주사액및주입액 Download PDF

Info

Publication number
KR100505772B1
KR100505772B1 KR10-1998-0705697A KR19980705697A KR100505772B1 KR 100505772 B1 KR100505772 B1 KR 100505772B1 KR 19980705697 A KR19980705697 A KR 19980705697A KR 100505772 B1 KR100505772 B1 KR 100505772B1
Authority
KR
South Korea
Prior art keywords
solution
additives
infusions
osmotic pressure
injections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1998-0705697A
Other languages
English (en)
Korean (ko)
Other versions
KR19990081979A (ko
Inventor
울리히 쉬페크
가브릴레 슈만-기암피리
페터 무쉬크
베르너 크라우제
Original Assignee
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 악티엔게젤샤프트 filed Critical 쉐링 악티엔게젤샤프트
Publication of KR19990081979A publication Critical patent/KR19990081979A/ko
Application granted granted Critical
Publication of KR100505772B1 publication Critical patent/KR100505772B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-1998-0705697A 1996-01-25 1997-01-27 개선된정맥투여용농축주사액및주입액 Expired - Fee Related KR100505772B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095.7 1996-01-25
DE19604095 1996-01-25

Publications (2)

Publication Number Publication Date
KR19990081979A KR19990081979A (ko) 1999-11-15
KR100505772B1 true KR100505772B1 (ko) 2005-10-25

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0705697A Expired - Fee Related KR100505772B1 (ko) 1996-01-25 1997-01-27 개선된정맥투여용농축주사액및주입액

Country Status (21)

Country Link
US (1) US6638913B1 (enExample)
EP (1) EP0876140B1 (enExample)
JP (1) JP2000505789A (enExample)
KR (1) KR100505772B1 (enExample)
CN (1) CN1209751A (enExample)
AT (1) ATE251893T1 (enExample)
AU (1) AU2150497A (enExample)
BG (1) BG62913B1 (enExample)
BR (1) BR9707081A (enExample)
CA (1) CA2244209C (enExample)
CZ (1) CZ234898A3 (enExample)
DE (2) DE59710863D1 (enExample)
DK (1) DK0876140T3 (enExample)
ES (1) ES2208884T3 (enExample)
HU (1) HUP9901355A3 (enExample)
IL (1) IL124676A0 (enExample)
NO (1) NO983438L (enExample)
PL (1) PL328199A1 (enExample)
PT (1) PT876140E (enExample)
SK (1) SK101398A3 (enExample)
WO (1) WO1997026862A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7419683B2 (en) 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
CZ302147B6 (cs) 1998-04-01 2010-11-18 Nortran Pharmaceuticals Inc. Aminocyklohexyletherová sloucenina, použití této slouceniny pri výrobe léciva, farmaceutická kompozice tuto slouceninu obsahující a tato sloucenina a kompozice pro použití pri lécení
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
BR122018009866B8 (pt) 2003-05-02 2021-07-27 Cardiome Pharma Corp métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MX2007005496A (es) 2004-11-08 2007-07-09 Cardiome Pharma Corp Nuevo regimen de dosificacion para compuestos moduladores de canal de iones, para el tratamiento de fibrilacion auricular aguda en un humano.
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) * 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
MX378185B (es) 2013-03-11 2025-03-07 Endomagnetics Ltd Soluciones hipoosmóticas para la detección de ganglio linfático.
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
EP2978454A1 (en) * 2013-03-27 2016-02-03 Ge Healthcare As Method and reagent for preparing a diagnostic composition
JP6821665B2 (ja) 2015-06-04 2021-01-27 エンドマグネティクス リミテッド 磁気マーカ
AU2019254483B2 (en) * 2018-04-16 2025-02-27 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013636A1 (en) * 1990-03-09 1991-09-19 Cockbain, Julian, Roderick, Michaelson Contrast media

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
AR222337A1 (es) * 1978-07-04 1981-05-15 Nyegaard & Co As Procedimiento para preparar una solucion esteril inyectable fisiologicamente aceptable de un agente de contraste de rayos x
JPS58500563A (ja) * 1981-04-27 1983-04-14 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド グルコ−ス、アミノ酸およびインシユリンを含む透析液
US4663289A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vitro use thereof
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE59007142D1 (de) 1990-01-18 1994-10-20 Cereria Amos Sgarbi Spa Grablicht.
DE4135193C1 (enExample) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013636A1 (en) * 1990-03-09 1991-09-19 Cockbain, Julian, Roderick, Michaelson Contrast media

Also Published As

Publication number Publication date
BG102644A (en) 1999-06-30
CN1209751A (zh) 1999-03-03
BG62913B1 (bg) 2000-11-30
AU2150497A (en) 1997-08-20
CZ234898A3 (cs) 1998-11-11
EP0876140A2 (de) 1998-11-11
HUP9901355A3 (en) 2000-06-28
HUP9901355A2 (hu) 1999-08-30
BR9707081A (pt) 1999-05-25
NO983438L (no) 1998-09-18
JP2000505789A (ja) 2000-05-16
DE19703816A1 (de) 1997-08-07
EP0876140B1 (de) 2003-10-15
CA2244209C (en) 2007-10-23
ATE251893T1 (de) 2003-11-15
US6638913B1 (en) 2003-10-28
WO1997026862A3 (de) 1997-10-23
IL124676A0 (en) 1998-12-06
WO1997026862A2 (de) 1997-07-31
ES2208884T3 (es) 2004-06-16
PT876140E (pt) 2004-02-27
PL328199A1 (en) 1999-01-18
SK101398A3 (en) 1998-12-02
DK0876140T3 (da) 2003-12-15
DE59710863D1 (de) 2003-11-20
KR19990081979A (ko) 1999-11-15
NO983438D0 (no) 1998-07-24
CA2244209A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
KR100505772B1 (ko) 개선된정맥투여용농축주사액및주입액
Schmidt et al. A better model of acute pancreatitis for evaluating therapy
CA2295140C (en) Stable insulin formulations
AU2016310475A1 (en) Rapid-acting insulin compositions
JPH0714882B2 (ja) 循環器系ショックに対する高浸透圧等塩素性製剤
CN107949374A (zh) 稳定的胰高血糖素溶液
EP1226829A2 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
WO2001041793A1 (fr) Formulation stable d'interferon en solution, son procede de preparation et ses applications
JPH02213A (ja) 生理活性ペプチド持続製剤
US6720011B1 (en) Injectable composition for cancer treatment
US12385017B2 (en) Acute respiratory distress syndrome therapeutic agent
DE60030722T2 (de) Hemmung der aufnahme schädigender proteine durch die nieren mit einer kombination von lysin und arginin
JPH06247872A (ja) 高濃度ｔｃｆ製剤
WO1991008765A1 (de) K2p pro-stabilisierung
NZ512486A (en) A solution having increased solubility for use in injectable drug products to treat acute pulmonary disorders
AU763521B2 (en) Improved concentrated injection and infusion solutions for intravascular use
JPH02229119A (ja) 動脈硬化予防および治療剤
JPS59181223A (ja) インタ−フエロンの安定化法
US4306553A (en) Method of maintaining the fluidity of hormone solutions for parenteral administration
JP2946015B2 (ja) 安定な抗ウィルス点滴用注射剤
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
JPH0386835A (ja) 劇症肝炎治療剤
JP2654518B2 (ja) 肝細胞増殖促進剤
JP3643879B2 (ja) 電解質輸液組成物
WO2001039741A2 (de) Mitomycin c-lösung

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E801 Decision on dismissal of amendment
PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20080727

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20080727

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000